Logo

Investment Bank Downgrades Waters on Q1 Profit Decline

Apr 28, 2006

NEW YORK, April 28 (GenomeWeb News) - Merrill Lynch yesterday cut Waters' stock to 'Neutral' from 'Buy' after the company said first-quarter income declined year over year.

 

As GenomeWeb News reported, Waters on Wednesday said first-quarter sales rose 8.2 percent atop increasing R&D spending and a narrowed profit.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.